Glaukos Stock Forecast, Price & News

Glaukos (NYSE:GKOS) Frequently Asked Questions

Is Glaukos a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos or view top-rated stocks.

How has Glaukos' stock price been impacted by COVID-19?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GKOS shares have increased by 17.8% and is now trading at $45.50.
View which stocks have been most impacted by COVID-19.

Are investors shorting Glaukos?

Glaukos saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 1,350,000 shares, a decline of 31.5% from the September 30th total of 1,970,000 shares. Based on an average daily trading volume, of 579,900 shares, the short-interest ratio is currently 2.3 days. Currently, 3.0% of the company's shares are short sold.
View Glaukos' Short Interest.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Glaukos.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) issued its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37. The medical instruments supplier earned $74.71 million during the quarter, compared to the consensus estimate of $72.73 million. Glaukos had a negative net margin of 13.05% and a negative trailing twelve-month return on equity of 4.12%. The company's quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the business earned ($0.09) earnings per share.
View Glaukos' earnings history.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285 million-$290 million, compared to the consensus revenue estimate of $287.86 million.

What price target have analysts set for GKOS?

9 Wall Street analysts have issued twelve-month target prices for Glaukos' stock. Their forecasts range from $34.00 to $105.00. On average, they anticipate Glaukos' share price to reach $58.56 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Glaukos or view top-rated stocks among Wall Street analysts.

Who are Glaukos' key executives?

Glaukos' management team includes the following people:

• Thomas William Burns, President, Chief Executive Officer & Director
• Chris M. Calcaterra, Chief Operating Officer
• Joseph E. Gilliam, CFO, CAO & Senior VP-Corporate Development (LinkedIn Profile)
• L. Jay Katz, Chief Medical Officer
• Tomas Navratil, Senior Vice President-Research & Development

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Glaukos' key competitors?

Some companies that are related to Glaukos include Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Beauty Health (SKIN), Inari Medical (NARI), Merit Medical Systems (MMSI), AtriCure (ATRC), Nevro (NVRO), iRhythm Technologies (IRTC), Axonics (AXNX), Haemonetics (HAE) and NuVasive (NUVA).
View all of GKOS's competitors.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (8.10%), Baillie Gifford & Co. (4.34%), Artisan Partners Limited Partnership (3.46%), Janus Henderson Group PLC (3.33%), Geode Capital Management LLC (1.61%) and Marshall Wace LLP (1.43%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

Which institutional investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Macquarie Group Ltd., New York State Common Retirement Fund, Artisan Partners Limited Partnership, Bellevue Group AG, Dimensional Fund Advisors LP, Citigroup Inc., and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos or view top insider-selling stocks.

Which institutional investors are buying Glaukos stock?

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Marshall Wace LLP, Balyasny Asset Management LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, and Healthcare of Ontario Pension Plan Trust Fund.
View insider buying and selling activity for Glaukos or or view top insider-buying stocks.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $45.50.

How much money does Glaukos make?

Glaukos has a market capitalization of $2.13 billion and generates $224.96 million in revenue each year. The medical instruments supplier earns $-120.35 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 653 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

Where are Glaukos' headquarters?

Glaukos is headquartered at 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at [email protected], or via fax at 949-367-9984.